San Francisco startup Composition Therapeutics is also focusing on an oral, the moment-daily GLP-one drug called GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June when a mid-stage study confirmed normal weight loss of around six% and it designs to get started on An additional mid-phase demo towards the tip of this yr—that found